The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date
Open accessAbstract
Osteoarthritis (OA) is a complex heterogeneous articular disease with multiple joint tissue involvement of varying severity and no regulatory-agency-approved disease-modifying drugs (DMOADs). In this review, we discuss the reasons necessitating the development of DMOADs for OA management, the classifications of clinical phenotypes or molecular/mechanistic endotypes from the viewpoint of targeted drug discovery, and then summarize the efficacy and safety profile of a range of targeted drugs in Phase 2 and 3 clinical trials directed to cartilage-driven, bone-driven, and inflammation-driven endotypes. Finally, we briefly put forward the reasons for failures in OA clinical trials and possible steps to overcome these barriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24131 · Cited by 2,516
The epidemiology and impact of pain in osteoarthritis
Neogi, T. (2013) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2013.03.018 · Cited by 1,730
Polymers for Drug Delivery Systems
Liechty, W. B., Kryscio, D. R., Slaughter, B. V., & Peppas, N. A. (2010) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-073009-100847 · Cited by 1,608
Jeon, O. H., Kim, C., Laberge, R.-M., Demaria, M., Rathod, S., Vasserot, A. P., Chung, J. W., Kim, D. H., Poon, Y., David, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4324 · Cited by 1,515
Fisetin is a senotherapeutic that extends health and lifespan
Yousefzadeh, M. J., Zhu, Y., McGowan, S. J., Angelini, L., Fuhrmann-Stroissnigg, H., Xu, M., Ling, Y. Y., Melos, K. I., Pirtskhalava, T., Inman, C. L., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.015 · Cited by 1,032
Loeser, R. F. (2009) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2009.03.002 · Cited by 726
Subchondral bone microenvironment in osteoarthritis and pain
Hu, Y., Chen, X., Wang, S., Jing, Y., & Su, J. (2021) · Bone Research · doi:10.1038/s41413-021-00147-z · Cited by 577
Stannus, O., Jones, G., Cicuttini, F., Parameswaran, V., Quinn, S., Burgess, J., & Ding, C. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.08.016 · Cited by 510
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302
Paracrine cellular senescence exacerbates biliary injury and impairs regeneration
Ferreira-Gonzalez, S., Lu, W.-Y., Raven, A., Dwyer, B., Man, T. Y., O’Duibhir, E., Lewis, P. J. S., Campana, L., Kendall, T. J., Bird, T. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03299-5 · Cited by 161
Cited by
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-05323-7 · Cited by 160
Metadata
- Authors
- Oo, W. M., Little, C., Duong, V., & Hunter, D. J.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-07
- Volume
- Volume 15
- Pages
- 2921-2945
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W3180056648
- Cited by
- 206
- References
- 10
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date. https://app.cochat.ai/papers/10.2147/dddt.s295224
- The paper
- Oo, W. M., Little, C., Duong, V., & Hunter, D. J. (2021). The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s295224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.